Team


DendroPharm was founded by Sam Dylan Moré, Henrik Luessen, Margret Moré, Emanuel Fleige, and Florian Paulus as a spin-off from the Freie Universität Berlin in 2013. We are dedicated to the development of novel excipients and innovative therapies for severe and chronic diseases.

The DendroPharm GmbH consists of a team of scientists with degrees in chemistry, synthetic organic chemistry, pharmacy, and microbiology. Our team cultivates a climate of integrity, creativity and commitment to our goal and vision: Satisfy customer requirements and expectations and to jointly make the world a better place. These values enable us to achieve a superior quality in products and services. In this process DendroPharm benefits extensively from the stimulating research climate and the technical infrastructure of our partner the Freie Universität Berlin.

We draw on more than 15 years of experience in technology transfer, industrial production, and quality management. Our scientists have spent prolonged periods in research institutes abroad, for example in India, Japan, the US, or Canada. In addition, some team members have held senior management or technical expert positions in the pharmaceutical industry.

Our regulatory expert has successfully completed more than 100 scientific and regulatory projects including regulatory dossiers, CMC parts, and the evaluation of clinical studies and scientific literature.

Our staff is fully trained to work according to ISO 9000 and GMP standards.



Dr. Sam Dylan Moré

Managing Director | Chemist | 12 years expertise in nanotechnological industry

Member of the "Commitee for Health Care Industry" of the Chamber of Commerce and Industry (IHK) Berlin

Dr. Margret Moré

Regulatory Affairs & Nonclinical Study Director | Microbiologist, 12 years expertise in regulatory affairs

Silvia Feddern

Accountant | 20 years working experience

Markus Zehringer

Quality Control | 14 years GMP expertise in industry